Pharmacokinetics and pharmacodynamic response of methylprednisolone in premenopausal renal transplant recipients

Journal of Clinical Pharmacology

Volumn 44, Issue 9, 2004, Pages 1003-1011

  Tornatore, Kathleen M ^a   Gilliland Johnson, Kristin K ^a   Farooqui, Mahfooz ^a   Reed, Kris A ^a   Venuto, Rocco C ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Adrenocorticotropin hormone; Glucocorticoids; Hypothalamic pituitary adrenal axis; Methylprednisolone; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AZATHIOPRINE; CORTICOTROPIN; CYCLOSPORIN A; FOLLITROPIN; HYDROCORTISONE; LUTEINIZING HORMONE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG CLEARANCE; FEMALE; HORMONE RELEASE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUTEAL PHASE; POSTOPERATIVE COMPLICATION; PREMENOPAUSE;

ADRENOCORTICOTROPIC HORMONE; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-INFLAMMATORY AGENTS; AREA UNDER CURVE; BODY WEIGHT; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HALF-LIFE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; METHYLPREDNISOLONE; MIDDLE AGED; PREMENOPAUSE;

EID: 4143053490     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004268130     Document Type: Article

References (32)

1. US Renal Data System. USRDS 2000 Annual Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Disease, 2000.
2. Halloran P, Melk A. Immunosuppressive agents used in transplantation. In: Johnson RJ, Feebally J, eds. Comprehensive Clinical Nephrology. Toronto, Canada: Mosby, 2000;85.1-85.12.
3. Tyrell JB. Glucocorticoid therapy. In: Felig P, Baxter JD, Frohman, LA, eds. Endocrinology and Metabolism. Toronto, Canada: McGraw-Hill, 1995;855-881.
4. Tornatore KM, Biocevich DM, Reed K, et al. Methylprednisolone pharmacokinetics, cortisol response, and adverse effects in black and white renal transplant recipients. Transplantation. 1995;59:729-736.
5. Tornatore KM, Reed K, Venuto RC. Racial differences in the pharmacokinetics of methylprednisolone in black and white renal transplant recipients. Pharmacotherapy. 1993;13:481-486.
6. Truhan AP, Ahmed AR. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy. 1989;62:375-389.
7. Gambertoglio JG, Vincenti F, Feduska NJ, et al. Prednisolone disposition in Cushingoid and non-Cushingoid kidney transplant patients. J Clin Endocrinol Metab. 1980;51:561-565.
8. Benet LZ, Frey FJ, Amend WJC, et al. Endogenous and exogenous glucocorticoids in Cushingoid patients. Drug Intellig Pharm. 1982;16:863-868.
9. Frey FJ, Ament JC, Lozada F, et al. Endogenous hydrocortisone: a possible factor contributory to the genesis of Cushingoid habitus in patients on prednisone. J Clin Endocrin Metab. 1981;53:1076-1080.
10. Kashuba ADM, Nafziger A. Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs. Clin Pharmacokinet. 1998;34:203-218.
11. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995;50:222-239.
12. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharamcokinet. 2002;41:329-342.
13. Lew KH, Ludwig EA, Milad MA, et al. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharm Ther. 1993;54:402-414.
14. Ebling WF, Szefler SJ, Jusko WJ. Analysis of cortisol, methylprednisolone, and methylprednisolone hemisuccinate. J Chromatogr. 1984;305:271-280.
15. Bolton S. Pharmaceutical Statistics: Practical and Clinical Applications. New York: Marcel Dekker, 1990.
16. Lausten GS, Egfjord M, Olgaard K. Metabolism of prednisone in kidney transplanted patients with necrosis of the femoral head. Pharmacol Toxicol. 1993;72:78-83.
17. Morley JE. Hormones, aging, and endocrine disorders in the elderly. In: Felig P, Baxter JD, Broadus AE, eds. Endocrinology and Metabolism. Toronto, Canada: McGraw-Hill, 1987;788-817.
18. Shapiro R, Carroll PB, Tzakis AG, et al. Adrenal reserve in renal transplant recipients with cyclosporine, azathioprine and prednisone immunosuppression. Transplantation. 1990;49:1011.
19. Slayter KL, Ludwig EA, Lew KH, et al. Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharm Ther. 1996;59:312-321.
20. Hunt CM, Westerkam WR, Stsave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992;44:275-283.
21. Schmucker DL, Woodhouse KW, Wang RK, et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharm Ther. 1990;48:365-374.
22. Sotaniemi EA, Pelkonen O, Arranto AJ, Tapanaienen P, Rautio A, Pasanen M. Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement. Pharmacol Toxicol. 2002;90:155-160.
23. Kharasch ED, Russell M, Garton K, Lentz G, Bowdle TA, Cox K. Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe. Anesthesiology. 1997;87:26-35.
24. Booker BM, Magee MH, Blum RA, Lates CD, Jusko WJ. Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. Clin Pharmacol Ther. 2002;72:370-382.
25. Bateman A, Singh A, Kral T, Solomon S. The immune-hypothalamic-pituitary- adrenal axis. Endocrinol Rev. 1989;10:92-112.
26. Sarna S, Hoppu K, Neuvonen PJ, Laine J, Holmberg C. Methylprednisolone exposure, rather than dose, predicts adrenal suppression and growth inhibition in children with liver and renal transplants. J Clin Endocrinol Metab. 1997;82:75-77.
27. Shapiro R, Carroll PB, Tzakis AG, et al. Adrenal reserve in renal transplant recipients with cyclosporine, azathioprine and prednisone immunosuppression. Transplantation. 1990;49:1011.
28. Kozaki M, Hirano T, Oka K. Adrenal function as an index of the immunosuppressive activity of glucocorticoids (prednisolone) in renal allograft recipients. Transplant Proc. 1987;19:2237.
29. Kozaki M, Hirano T, Oka K, et al. Postoperative endogenous serum cortisol levels as an index of acute rejection and severe infection in renal allograft recipients. Transplant Proc. 1989;21:1864.
30. Hricik DE, Almawi WY, Strom TB. Trends in the use of glucocorticoids in renal transplantation. Transplantation. 1994;57:979-989.
31. Tornatore KM, Reed K, Walshe J, et al. Cortisol pharmacodynamic response to long-term methylprednisolone in renal transplant recipients. Pharmacotherapy. 1994;14:111-118.
32. Dumler F, Levin NW, Szego G, et al. Long-term alternate day steroid therapy in renal transplantation. Transplantation. 1982:34:78-82.